当前位置: 首页 >> 检索结果
1. Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial.
作者: Junqi Niu.;Yanhang Gao.;Guiqiang Wang.;Zhijie Qin.;Cuisong Wu.;Zujiang Yu.;Lichun Wang.;Zhongjie Hu.;Xing Li.;Zong Zhang.;Yue Chen.;Lvfeng Yao.;Jinhui Yang.;Guang-Ming Li.;Yida Yang.;Xiaobo Lu.;Ye Gu.;Xiaofeng Wu.;Xiaorong Mao.;Zhongyin Zhou.;Jia Shang.;Bingliang Lin.;Ji-Dong Jia.;Fengmei Wang.;Jiming Zhang.;Hongyan Ma.;Xinrui Wang.;Cliff Y Yang.;Daichang Yang.
来源: Gut. 2025年74卷9期1476-1485页
Despite inadequate supply and potential contamination risk, human plasma has remained the only source for human serum albumin (pHSA) intravenous administration since the 1940s.
2. Prophylactic clip closure after endoscopic submucosal dissection of large flat and sessile colorectal polyps: a multicentre randomised controlled trial (EPOC trial).
作者: Akihiro Miyakawa.;Yuzuru Tamaru.;Takeshi Mizumoto.;Noriyoshi Kanazawa.;Shiori Uchiyama.;Kosuke Maehara.;Yorinobu Sumida.;Akira Nakamura.;Ei Itobayashi.;Haruhisa Shimura.;Yoshio Suzuki.;Tomoyuki Akita.;Kenji Shimura.;Toshio Kuwai.
来源: Gut. 2025年74卷11期1814-1820页
Prophylactic clip closure after endoscopic mucosal resection reduces delayed bleeding in large and proximal colon lesions; however, evidence regarding its effectiveness in colorectal endoscopic submucosal dissection (ESD) is lacking.
3. Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis.
作者: Virginia Mela.;Violeta Heras.;Monika Iesmantaite.;María Luisa García-Martín.;Manuel Bernal.;Joel D Posligua-García.;Alba Subiri-Verdugo.;José Ignacio Martínez-Montoro.;Ana María Gómez-Pérez.;Borja Bandera.;Isabel Moreno-Indias.;Francisco J Tinahones.
来源: Gut. 2025年74卷11期1828-1846页
Obesity-related cognitive decline is linked to gut microbiota dysbiosis, with emerging evidence suggesting that dietary interventions may ameliorate cognitive impairment via gut-brain axis modulation. The role of microglial cells in this process remains underexplored.
4. Parecoxib sequential with imrecoxib for occurrence and remission of severe acute pancreatitis: a multicentre, double-blind, randomised, placebo-controlled trial.
作者: Luming Huang.;Zhe Feng.;Wenjuan Yang.;Yin Zhu.;Jing Li.;Libin Huang.;Rui Wang.;Lan Peng.;Mingshun He.;Yingmei Tang.;Ping Chen.;Cheng Lan.;Xiaoqing Zhou.;Lin Zhou.;Cheng Ye.;Linhao Zhang.;Jingsun Jiang.;Yanting Ye.;Rui Wang.;Yan He.;Yan Liu.;Hui Gong.;Huifang Xiong.;Liang Xia.;Haiyan Xu.;Bin Zhang.;Rongfang Tu.;Chun Du.;Lujia Cui.;Jinhang Gao.;Zhiyin Huang.;Chengwei Tang.
来源: Gut. 2025年74卷9期1467-1475页
There is no effective drug treatment for the organ failure (OF) caused by severe acute pancreatitis (SAP).
5. Choice of colon capsule or colonoscopy versus default colonoscopy in FIT positive patients in the Danish screening programme: a parallel group randomised controlled trial.
作者: Gunnar Baatrup.;Thomas Bjørsum-Meyer.;Lasse Kaalby.;Benedicte Schelde-Olesen.;Morten Kobaek-Larsen.;Anastasios Koulaouzidis.;Rasmus Kroijer.;Issam Al-Najami.;Niels Buch.;Anders Høgh.;Niels Qvist.;Marianne Kirstine Thygesen.;Ulrik Deding.; .
来源: Gut. 2025年74卷10期1616-1623页
Colonoscopy is among the standard tests for colorectal cancer (CRC) screening. However, uptake varies, and alternatives such as colon capsule endoscopy (CCE) are available. The uptake and detection rate of clinically significant neoplasia with CCE, compared with colonoscopy, remain unclear in this setting.
6. Multicentre randomised controlled trial of a self-assembling haemostatic gel to prevent delayed bleeding following endoscopic mucosal resection (PURPLE Trial).
作者: Jan Drews.;Markus Zachäus.;Tobias Kleemann.;Jörg Schirra.;Oscar Cahyadi.;Oliver Möschler.;Christian Schulze.;Ingo Steinbrück.;Edris Wedi.;Oliver Pech.;Tobias J Weismüller.;Armin Küllmer.;Mohamed Abdelhafez.;Jochen Wedemeyer.;Torsten Beyna.;Julian Riedel.;Ulrich Paul Halm.;Carola Güther.;Riccardo Vasapolli.;Christian Torres Reyes.;Daniel R Quast.;Oliver Bachmann.;Erini Dedonaki.;Jörg Ulrich.;Inna Marchuk.;Christina Frahm.;Tanja Steffen.;Peter Wohlmuth.;Torsten Bunde.;Nele Geßler.;Thomas von Hahn.
来源: Gut. 2025年74卷7期1103-1111页
Prophylactic application of a haemostatic gel to the resection field may be an easy way to prevent delayed bleeding, a frequent complication after endoscopic mucosal resection (EMR).
7. Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab.
作者: Yuta Myojin.;Sepideh Babaei.;Rajiv Trehan.;Christoph Hoffman.;Noemi Kedei.;Benjamin Ruf.;Mohamed-Reda Benmebarek.;Kylynda C Bauer.;Patrick Huang.;Chi Ma.;Cecilia Monge.;Changqing Xie.;Donna Hrones.;Austin G Duffy.;Paul Armstrong.;Lorenz Kocheise.;Fiona Desmond.;Jemma Buchalter.;Marie Galligan.;Colin Cantwell.;Ronan Ryan.;Jeff McCann.;Michele Bourke.;Ross Mac Nicholas.;Ray McDermott.;Joy Awosika.;Maggie Cam.;Rosanna Krebs.;Anuradha Budhu.;Mahler Revsine.;William D Figg.;David E Kleiner.;Bernadette Redd.;Bradford J Wood.;Xin Wei Wang.;Firouzeh Korangy.;Manfred Claassen.;Tim F Greten.
来源: Gut. 2025年74卷6期983-995页
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC.
8. Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.
作者: Daniela Guisado.;Sayali Talware.;Xiaoli Wang.;Andrew Davis.;Elbek Fozilov.;Aaron Etra.;Jean-Frederic Colombel.;Christoph Schaniel.;Christopher Tastad.;John E Levine.;James L M Ferrara.;Chuang Ling-Shiang.;Ksenija Sabic.;Shishir Singh.;Bridget K Marcellino.;Ronald Hoffman.;Judy Cho.;Louis Cohen.
来源: Gut. 2025年74卷6期894-905页
Treatment strategies for Crohn's disease (CD) suppress diverse inflammatory pathways but many patients remain refractory to treatment. Autologous haematopoietic stem cell transplantation (SCT) is an emerging therapy for medically refractory CD though the mechanisms through which it circumvents refractory pathophysiology are unknown.
9. Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
作者: Javier P Gisbert.;María G Donday.;Sabino Riestra.;Alfredo J Lucendo.;José-Manuel Benítez.;Mercè Navarro-Llavat.;Jesús Barrio.;Víctor J Morales-Alvarado.;Montserrat Rivero.;David Busquets.;Eduardo Leo Carnerero.;Olga Merino.;Óscar Nantes Castillejo.;Pablo Navarro.;Manuel Van Domselaar.;Ana Gutiérrez.;Inmaculada Alonso-Abreu.;Rafael Mejuto.;Luis Fernández-Salazar.;Marisa Iborra.;María Dolores Martín-Arranz.;Juan Ramón Pineda.;Manuela Josefa Sampedro.;Katja Serra Nilsson.;Abdel Bouhmidi.;Lissette Batista.;Carmen Muñoz Villafranca.;Iago Rodríguez-Lago.;Daniel Ceballos.;Iván Guerra.;Miriam Mañosa.;Ignacio Marín Jiménez.;Emilio Torrella.;Maribel Vera Mendoza.;María José Casanova.;Ruth de Francisco.;Laura Arias-González.;Sandra Marín Pedrosa.;Orlando García-Bosch.;Francisco Javier García-Alonso.;Pedro Delgado-Guillena.;María José García.;Leyanira Torrealba.;Andrea Núñez-Ortiz.;Miren Vicuña Arregui.;Marta Maia Bosca-Watts.;Isabel Blázquez.;Diana Acosta.;Ana Garre.;Montse Baldán.;Concepción Martínez.;Manuel Barreiro-de Acosta.;Eugeni Domènech.;Maria Esteve.;Valle García-Sánchez.;Pilar Nos.;Julián Panés.;María Chaparro.; .
来源: Gut. 2025年74卷3期387-396页
Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment versus those who maintain it.
10. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases.
作者: Yuanfang Li.;Yongqiang Zheng.;Jiaqian Huang.;Run-Cong Nie.;Qi-Nian Wu.;Zhijun Zuo.;Shuqiang Yuan.;Kai Yu.;Cheng-Cai Liang.;Yi-Qian Pan.;Bai-Wei Zhao.;Yuhong Xu.;Qihua Zhang.;Yashang Zheng.;Junquan Chen.;Zhao-Lei Zeng.;Wei Wei.;Ze-Xian Liu.;Rui-Hua Xu.;Hui-Yan Luo.
来源: Gut. 2025年74卷3期350-363页
Peritoneal metastasis is the most common metastasis pattern of gastric cancer. Patients with gastric cancer peritoneal metastasis (GCPM) have a poor prognosis and respond poorly to conventional treatments. Recently, immune checkpoint blockade (ICB) has demonstrated favourable efficacy in the treatment of GCPM. Stratification of best responders and elucidation of resistance mechanisms of ICB therapies are highly important and remain major clinical challenges.
11. Combined MRI, high-resolution manometry and a randomised trial of bisacodyl versus hyoscine show the significance of an enlarged colon in constipation: the RECLAIM study.
作者: Victoria Wilkinson-Smith.;Mark Scott.;Alex Menys.;Lukasz Wiklendt.;Luca Marciani.;David Atkinson.;Stefano Sansone.;Ausra Zdanaviciene.;Carol Coupland.;Charles H Knowles.;Philip Dinning.;Stuart A Taylor.;Penny Gowland.;Caroline Louise Hoad.;Maura Corsetti.;Robin C Spiller.
来源: Gut. 2024年74卷1期35-44页
Colonic motility in constipation can be assessed non-invasively using MRI.
12. External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
作者: Nicolas Pierre.;Vân Anh Huynh-Thu.;Dominique Baiwir.;Gabriel Mazzucchelli.;Maximilien Fléron.;Lisette Trzpiot.;Gauthier Eppe.;Edwin De Pauw.;David Laharie.;Jack Satsangi.;Peter Bossuyt.;Lucine Vuitton.;Sophie Vieujean.;Jean-Frédéric Colombel.;Marie-Alice Meuwis.;Edouard Louis.; .
来源: Gut. 2024年73卷12期1965-1973页
In patients with Crohn's disease (CD) on combination therapy (infliximab and immunosuppressant) and stopping infliximab (cohort from the study of infliximab diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors (STORI)), the risk of short-term (≤6 months) and mid/long-term relapse (>6 months) was associated with distinct blood protein profiles. Our aim was to test the external validity of this finding in the SPARE cohort (A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy).
13. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
作者: Andrea Vecchi.;Marzia Rossi.;Camilla Tiezzi.;Paola Fisicaro.;Sara Doselli.;Elena Adelina Gabor.;Amalia Penna.;Ilaria Montali.;Camilla Ceccatelli Berti.;Valentina Reverberi.;Anna Montali.;Simon P Fletcher.;Elisabetta Degasperi.;Dana Sambarino.;Diletta Laccabue.;Floriana Facchetti.;Simona Schivazappa.;Elisabetta Loggi.;Barbara Coco.;Daniela Cavallone.;Elena Rosselli Del Turco.;Marco Massari.;Giuseppe Pedrazzi.;Gabriele Missale.;Gabriella Verucchi.;Pietro Andreone.;Maurizia Rossana Brunetto.;Pietro Lampertico.;Carlo Ferrari.;Carolina Boni.
来源: Gut. 2024年73卷10期1737-1748页
Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-α) and nucleos(t)ides (NUCs). The aim of our study was to assess the immunomodulatory effect of pegIFN-α on T and natural killer (NK) cell responses in NUC-suppressed patients to identify cellular and/or serological parameters to predict better T cell-restoring effect and better control of infection in response to pegIFN-α for a tailored application of IFN-α add-on.
14. Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy.
作者: Wen Gao.;Jianxiang Liu.;Xiaolei Wang.;Jingwen Li.;Xuezhi Zhang.;Hui Ye.;Jiang Li.;Xinhong Dong.;Binbin Liu.;Chi Wang.;Ying Xu.;Guigen Teng.;Yuling Tian.;Jinpei Dong.;Chaoyi Ge.;Hong Cheng.
来源: Gut. 2024年73卷9期1414-1420页
This study aimed to evaluate the efficacy and safety of vonoprazan and tetracycline (VT) dual therapy as first-line treatment for Helicobacter pylori infection in patients with penicillin allergy.
15. Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial.
作者: Amit G Singal.;Manasa Narasimman.;Darine Daher.;Sruthi Yekkaluri.;Yan Liu.;MinJae Lee.;Vanessa Cerda.;Aisha Khan.;Karim Seif El Dahan.;Jennifer Kramer.;Purva Gopal.;Caitlin Murphy.;Ruben Hernaez.
来源: Gut. 2024年73卷12期2037-2044页
Hepatocellular carcinoma (HCC) is plagued by failures across the cancer care continuum, leading to frequent late-stage diagnoses and high mortality. We evaluated the effectiveness of mailed outreach invitations plus patient navigation to promote HCC screening process completion in patients with cirrhosis.
16. Hypoxia-inducible factor-1α mediates reflux-induced epithelial-mesenchymal plasticity in Barrett's oesophagus patients.
作者: Qiuyang Zhang.;Kerry B Dunbar.;Robert D Odze.;Agoston T Agoston.;Xuan Wang.;Tianhong Su.;Anh D Nguyen.;Xi Zhang.;Stuart Jon Spechler.;Rhonda F Souza.
来源: Gut. 2024年73卷8期1269-1279页
Epithelial-mesenchymal plasticity (EMP), the process through which epithelial cells acquire mesenchymal features, is needed for wound repair but also might contribute to cancer initiation. Earlier, in vitro studies showed that Barrett's cells exposed to acidic bile salt solutions (ABS) develop EMP. Now, we have (1) induced reflux oesophagitis in Barrett's oesophagus (BO) patients by stopping proton pump inhibitors (PPIs), (2) assessed their biopsies for EMP and (3) explored molecular pathways underlying reflux-induced EMP in BO cells and spheroids.
17. Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.
作者: Ruben Y Gabriëls.;Anne M van der Waaij.;Matthijs D Linssen.;Michael Dobosz.;Pia Volkmer.;Sumreen Jalal.;Dominic Robinson.;Marcela A Hermoso.;Marjolijn N Lub-de Hooge.;Eleonora A M Festen.;Gursah Kats-Ugurlu.;Gerard Dijkstra.;Wouter B Nagengast.
来源: Gut. 2024年73卷9期1454-1463页
Improving patient selection and development of biological therapies such as vedolizumab in IBD requires a thorough understanding of the mechanism of action and target binding, thereby providing individualised treatment strategies. We aimed to visualise the macroscopic and microscopic distribution of intravenous injected fluorescently labelled vedolizumab, vedo-800CW, and identify its target cells using fluorescence molecular imaging (FMI).
18. Short-duration selective decontamination of the digestive tract infection control does not contribute to increased antimicrobial resistance burden in a pilot cluster randomised trial (the ARCTIC Study).
作者: Iain Robert Louis Kean.;John A Clark.;Zhenguang Zhang.;Esther Daubney.;Deborah White.;Paloma Ferrando-Vivas.;Gema Milla.;Brian Cuthbertson.;John Pappachan.;Nigel Klein.;Paul Mouncey.;Kathy Rowan.;John Myburgh.;Theodore Gouliouris.;Stephen Baker.;Julian Parkhill.;Nazima Pathan.; Arctic Research Team.
来源: Gut. 2024年73卷6期910-921页
Selective decontamination of the digestive tract (SDD) is a well-studied but hotly contested medical intervention of enhanced infection control. Here, we aim to characterise the changes to the microbiome and antimicrobial resistance (AMR) gene profiles in critically ill children treated with SDD-enhanced infection control compared with conventional infection control.
19. Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial.
作者: Jiaying Zhu.;Chuqing Sun.;Min Li.;Guoru Hu.;Xing-Ming Zhao.;Wei-Hua Chen.
来源: Gut. 2024年73卷7期1087-1097页
We aim to compare the effects of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on the gut microbiota through longitudinal analysis.
20. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
作者: Albert J Bredenoord.;Evan S Dellon.;Ikuo Hirano.;Alfredo J Lucendo.;Christoph Schlag.;Xian Sun.;Lila Glotfelty.;Leda Mannent.;Jennifer Maloney.;Elizabeth Laws.;Eric Mortensen.;Arsalan Shabbir.
来源: Gut. 2024年73卷3期398-406页
To assess the effect of long-term dupilumab on histological, symptomatic and endoscopic aspects of eosinophilic oesophagitis (EoE) in adolescent and adult patients with and without prior use of swallowed topical corticosteroids (STC) or prior inadequate response, intolerance or contraindication to STC.
|